Massey Quick Simon & CO. LLC acquired a new stake in Illumina, Inc. (NASDAQ:ILMN) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 6,000 shares of the life sciences company’s stock, valued at approximately $1,195,000.
Several other hedge funds have also recently added to or reduced their stakes in the stock. First Citizens Bank & Trust Co. grew its stake in Illumina by 0.4% in the second quarter. First Citizens Bank & Trust Co. now owns 3,088 shares of the life sciences company’s stock valued at $536,000 after purchasing an additional 12 shares during the last quarter. Puzo Michael J grew its stake in shares of Illumina by 0.4% during the second quarter. Puzo Michael J now owns 5,955 shares of the life sciences company’s stock worth $1,032,000 after acquiring an additional 25 shares during the last quarter. Flagship Harbor Advisors LLC grew its stake in shares of Illumina by 1.7% during the second quarter. Flagship Harbor Advisors LLC now owns 2,046 shares of the life sciences company’s stock worth $345,000 after acquiring an additional 35 shares during the last quarter. Broderick Brian C grew its stake in shares of Illumina by 0.3% during the second quarter. Broderick Brian C now owns 13,152 shares of the life sciences company’s stock worth $2,282,000 after acquiring an additional 40 shares during the last quarter. Finally, Nordea Investment Management AB grew its stake in shares of Illumina by 0.6% during the second quarter. Nordea Investment Management AB now owns 6,798 shares of the life sciences company’s stock worth $1,180,000 after acquiring an additional 42 shares during the last quarter. Hedge funds and other institutional investors own 92.70% of the company’s stock.
Shares of Illumina, Inc. (NASDAQ ILMN) traded down $3.84 during trading hours on Tuesday, reaching $205.30. The company’s stock had a trading volume of 182,394 shares, compared to its average volume of 967,756. The company has a current ratio of 4.22, a quick ratio of 3.73 and a debt-to-equity ratio of 0.41. The stock has a market cap of $30,505.24, a PE ratio of 61.09, a P/E/G ratio of 3.45 and a beta of 0.74. Illumina, Inc. has a 12 month low of $119.37 and a 12 month high of $214.50.
Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.99 by $0.12. The company had revenue of $714.00 million during the quarter, compared to analysts’ expectations of $692.77 million. Illumina had a return on equity of 19.42% and a net margin of 30.34%. The firm’s quarterly revenue was up 17.6% on a year-over-year basis. During the same period in the prior year, the business earned $0.97 EPS. analysts predict that Illumina, Inc. will post 3.75 EPS for the current year.
A number of equities research analysts have recently weighed in on the company. Zacks Investment Research lowered Illumina from a “buy” rating to a “hold” rating in a research note on Tuesday, October 31st. Citigroup Inc. boosted their price target on Illumina from $180.00 to $220.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 25th. Barclays PLC lifted their target price on Illumina from $150.00 to $185.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 25th. Bank of America Corporation lifted their target price on Illumina from $215.00 to $240.00 and gave the stock a “buy” rating in a report on Wednesday, October 25th. Finally, Wells Fargo & Company reaffirmed a “market perform” rating and set a $205.00 target price (up previously from $200.00) on shares of Illumina in a report on Wednesday, October 25th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and thirteen have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $200.88.
In other news, Director Jay T. Flatley sold 22,540 shares of the stock in a transaction on Tuesday, August 29th. The stock was sold at an average price of $195.21, for a total transaction of $4,400,033.40. Following the completion of the transaction, the director now directly owns 539,176 shares in the company, valued at approximately $105,252,546.96. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Jay T. Flatley sold 2,540 shares of the stock in a transaction on Monday, August 28th. The stock was sold at an average price of $197.39, for a total value of $501,370.60. Following the transaction, the director now owns 539,176 shares of the company’s stock, valued at $106,427,950.64. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 167,964 shares of company stock valued at $34,559,469. 1.60% of the stock is owned by company insiders.
COPYRIGHT VIOLATION NOTICE: This report was first posted by Transcript Daily and is the property of of Transcript Daily. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://transcriptdaily.com/2017/11/14/6000-shares-in-illumina-inc-ilmn-acquired-by-massey-quick-simon-co-llc.html.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.